Parameters of captopril challenge test can predict results of other confirmatory tests for primary aldosteronism and propose the next test to be done

• Published in: Endocrine Journal Vol. 67; no. 7; pp. 741 - 750
• Main Authors: Tamura, Naohisa, Yamada, Kanako, Hatakeyama, Hiroshi, Torii-Hanakita, Mizuki, Kyo, Chika, Kosugi, Rieko, Yonemoto, Takako, Ogawa, Tatsuo, Kotani, Masato, Usui, Takeshi, Inoue, Tatsuhide
• Format: Journal Article
• Language: English
• Published: Japan The Japan Endocrine Society 01.01.2020; Japan Science and Technology Agency
• Subjects: Aldosterone; Captopril challenge test; Confirmatory tests; Diagnosis; Endocrine disorders; Furosemide; Primary aldosteronism; Relation; Renin; Relation; Diagnosis; Primary aldosteronism; Captopril challenge test; Confirmatory tests
• ISSN: 0918-8959; 1348-4540
• DOI: 10.1507/endocrj.EJ19-0498

In Japan, primary aldosteronism (PA) is diagnosed if any one of the captopril challenge test (CCT), saline infusion test (SIT), furosemide-upright test (FUP), and oral salt-loading test (OST) is positive. The present study aimed to investigate if parameters of CCT, the safest confirmatory test, could predict decisions of other tests and propose the next test to diagnose PA in CCT-negative patients. In a cross-sectional design, 142 patients, who were referred to our hospital for the scrutiny of PA and underwent at least two confirmatory tests, were enrolled. While 123 patients underwent all of the CCT, SIT, and FUP, the OST was successfully done in only six patients and excluded from further analyses. CCT parameters showing correlations of higher degrees with SIT and FUP parameters were selected, and their powers to predict SIT and FUP decisions were investigated by receiver operating characteristic analyses. Proposals of the next test based on the CCT parameters were validated with SIT and FUP decisions in subsets of CCT-negative patients divided by cut-offs of the CCT parameters. The plasma aldosterone concentration and plasma renin activity 60 min after the load of CCT (CCT60-PAC and CCT60-PRA) were selected, and CCT60-PAC ≤59.0 pg/mL and CCT60-PRA ≥1.05 ng/mL/h could predict negativities of SIT and FUP, respectively, with >95% specificities. Based on the validation, the present study suggested the SIT as the next test to be done if the CCT-negative patient belonged to the subset with CCT60-PAC >59.0 pg/mL and CCT60-PRA ≥1.05 ng/mL/h, otherwise the FUP should be selected.